SO-009

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer

Authors

Cutsem

E Van

Machiels

den Eynde

M Van

Prenen

⁴

Hendlisz

⁵

Shaza

⁵

Carrasco

⁶

Canon

⁷

Sotiropoulou

⁸

Breman

⁸

Alcantar

⁸

Flament

⁸

1University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium

2St-Luc University Hospital, Brussels, Belgium 3Clin. Univ. St-Luc Bruxelles, Brussels, Belgium 4University Hospital Gasthuisberg, Leuven, Belgium 5Institut Jules Bordet, Brussels, Belgium 6Grand Hôpital de Charleroi, Charleroi, Belgium 7Service d’Oncologie-Hématologie, Grand Hôpital de Charleroi, Charleroi, Belgium 8Celyad, Mont-Saint-Guibert, Belgium

Newsroom

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer